Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
9.68
+0.04 (0.36%)
Aug 6, 2025, 2:24 PM - Market open

Company Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) logo
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees74
CEORobert Barrow

Contact Details

Address:
One World Trade Center, Suite 8500
New York, New York 10007
United States
Phone212 220 6633
Websitemindmed.co

Stock Details

Ticker SymbolMNMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001813814
CUSIP Number60255C109
ISIN NumberCA60255C8850
SIC Code2833

Key Executives

NamePosition
Robert BarrowChief Executive Officer and Director
Mark R. Sullivan J.D.Chief Legal Officer and Corporate Secretary
Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer
Dr. Scott M. Freeman M.D.Co-Founder and Clinical Advisor
Leonard LatchmanCo-Founder
Brandi L. Roberts CPA, M.B.A.Chief Financial Officer
Peter MackSenior Vice President of Pharmaceutical Development and Operations
Beth CalitriVice President of Corporate Communications
Stephanie FaganChief Corporate Affairs Officer
Dr. Gregg Pratt Ph.D.Chief Regulatory and Quality Assurance Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 202510-QQuarterly Report
Jul 31, 20258-KCurrent Report
Jun 25, 2025144Filing
Jun 25, 2025144Filing
Jun 25, 2025144Filing
Jun 20, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 16, 20258-KCurrent Report
May 27, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report